2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Use of Inappropriate Antipsychotics Among US Long-Term Care Residents with Parkinson’s Disease Psychosis

D. Kremens, V. Abler, S. Andes, N. Rashid, A. Shim (Philadelphia, PA, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Use of syringe driver in End of Life Care in Parkinson’s Disease (PD)

N. Butt, M. Khwaja, A. Chatterjee (Reading, United Kingdom)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

Usefulness of Heart Rate Variability to Identify the Risk of Falling in Huntington’s Disease

C. Terroba-Chambi, D. Vigo, M. Merello (Buenos Aires, Argentina)

Huntington’s Disease  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Using cognitive computing to identify existing drugs with potential to stabilize mitophagy pathways associated with Parkinson’s Disease

N. Visanji, N. Moskal, G. Shi, A. Lacoste, S. Spangler, P. Lewis, A. Mcquibban (Toronto, ON, Canada)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Using functional status to aid interpretation of cUHDRS scores in patients with Huntington’s disease

D. Trundell, G. Palermo, J. Long, B. Leavitt, S. Schobel, S. Tabrizi (Welwyn Garden City, United Kingdom)

Huntington’s Disease  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Using whole genome sequencing and intronic sequence analysis to identify pathogenic variants in Parkin-related Parkinson’s Disease

R. Davis, K. Kumar, F. Edema-Hildebrand, J-S. Park, B. Koentjoro, V. Gayevskiy, M. Cowley, N. Blair, C. Sue (St Leonards, Australia)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Utility of a smartphone app in discretely assessing and monitoring symptoms of Parkinson’s disease

N. Shaafi Kabiri, A. Best, S. Johnson, B. Ho, G. Eden, B. Dupee, M. Fedorovsky, J. Severson, D. Amato, B. Severson, J. Bhangu, J. Cosman, M. Erb, K. Thomas (Boston, MA, USA)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

Utilization of Monotherapy and Combination Therapies in Advanced Parkinson Disease Patients During Levodopa-Carbidopa Intestinal Gel Treatment from the COSMOS Study

A. Fasano, JC. Parra, T. Gurevich, R. Jech, N. Kovács, P. Svenningsson, J. Szász, L. Bergmann, A. Johnson, O. Sanchez-Soliño, Z. Tang, L. Vela-Desojo (Toronto, ON, Canada)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study

S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Bordeaux, France)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Validation of Acoustic Analysis of Swallowing as a Method of Screening for Orofaringeal Dysfunction at Parkinson

RSS. Santos, BSZ. Zeigelboim, GSS. Silva, MCN. Nunes, HGT. Teive (Curitiba, Brazil)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3